Levosimendan: A new era for inodilator therapy for heart failure?

Current Opinion in Cardiology

Volumn 17, Issue 3, 2002, Pages 257-265

  Cleland, John G F ^a,b   McGowan, James ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; CALCIUM SENSITIZER; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NESIRITIDE; PIMOBENDAN; PLACEBO; POTASSIUM CHANNEL; TROPONIN C; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART SURGERY; HEMODYNAMICS; HUMAN; HYPOTENSION; INOTROPISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYDRAZONES; PYRIDAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036116421     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200205000-00008     Document Type: Review

References (39)

1. The heart failure epidemic: Exactly how big is it?
2. Is the prognosis of heart failure improving?
3. Clinical trials update: Highlights of the scientific sessions of heart failure 2001, a meeting of the working group on heart failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF
4. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through adrenergic pathways in patients with heart failure: A meta-regression analysis
5. Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism
6. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan
7. Binding of a new Ca2+ - Sensitizer, levosimendan, to recombinant human cardiac troponin C
8. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C
9. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension
10. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation
11. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium
12. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anaesthetized dogs
13. Mechanisms of action of calcium-sensitizing drugs
14. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart
15. Intracoronary levosimendan enhances contractile function of stunned myocardium
16. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure
17. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization
18. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels
19. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein
20. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan
21. Effects of levosimendan on myocardial contractility and oxygen consumption
22. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting
23. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs
24. Haemodynamic dose-efficacy of levosimendan in healthy volunteers
25. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure
26. Haemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure
27. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function
28. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K-ATP channels
29. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: Relation to hemodynamic response
30. The positive inotropic agent levosimendan mediates increased cardiac output without progression of sympathovagal imbalance in patients with heart failure
31. Improved survival with simendan after experimental myocardial infarction in rats
32. Pharmokinetics of levosimendan in healthy volunteers and patients with congestive heart failure
33. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals
34. Site dependent bioavailability and metabolism of levosimendan in dogs
35. Efficacy and safety of intravenous levosimendan, a novel calcium sensitiser, in severe low output failure
36. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular heart failure after an acute myocardial infarction (the RUSSLAN study)
37. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
38. Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial